Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Lyell announced the discontinuation of the development of LYL797 to focus on the Phase 1 clinical trial of LYL119, which is expected to initiate enrollment of patients with platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer this year or early next year.Last week, Lyell Immunopharma Inc. (NASDAQ:LYEL) agreed to acquire ImmPACT Bio USA Inc., a privately owned clinical-stage biotechnology company.
上週，Lyell Immunopharma Inc. (納斯達克:LYEL)同意收購ImmPACt Bio USA Inc.，這是一傢俬人擁有的臨床生物技術公司。
Lyell has prioritized its pipeline to focus resources on its most differentiated CAR T-cell clinical programs, including IMPT-314 following the close of the acquisition and LYL119.
在收購完成後，Lyell已將其管線重點放在資源上，專注於其最具差異化的CAR T細胞臨床項目，包括IMPt-314和LYL119。
Also Read: Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
也可閱讀：利爾免疫製藥因CAR-T細胞治療癌症試驗中有一例患者死亡而股價暴跌
Lyell announced the discontinuation of the development of LYL797 to focus on the Phase 1 clinical trial of LYL119, which is expected to initiate enrollment of patients with platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer this year or early next year.
Lyell宣佈停止LYL797的開發，專注於LYL119的第1階段臨床試驗，預計今年或明年初開始招募鉑金耐藥性卵巢癌或復發/難治性子宮內膜癌的患者。
The LYL845 tumor-infiltrating lymphocyte (TIL) program is also being discontinued, as the clinical data in patients with advanced melanoma did not meet pre-determined criteria for continued development.
由於患有晚期黑色素瘤的患者的臨床數據未達到繼續開發的預定標準，LYL845腫瘤浸潤淋巴細胞（TIL）項目也將停止。
Its next-generation TIL and rejuvenation programs that are in preclinical development will also be discontinued.
其下一代TIL和復甦項目正在臨床前階段開發中，也將終止。
Lyell expects its cash balance to fund operations into 2027.
利爾預計其現金餘額將支持運營至2027年。
Deal terms include upfront consideration of $30 million in cash and 37.5 million Lyell shares.
交易條款包括3,000萬美元的現金和3750萬股利爾公司股份作爲前期考慮。
ImmPACT shareholders will also be eligible for contingent consideration consisting of 12.5 million Lyell shares and a low single-digit royalty on future net sales.
ImmPACt股東還將有資格獲得包括1250萬Lyell股份和未來淨銷售額低位數位的特許權考慮。
BofA Securities has downgraded Lyell from Buy to Underperform, with a price target of $1, down from $6.
美國銀行證券已將Lyell的買入評級下調至表現不佳，目標價從6美元下調至1美元。
The analyst said, "While discontinuation of '797 isn't a surprise, we think optimism is growing for next-gen '119's improved therapeutic window."
分析師表示：「儘管‘797的終止並不令人意外，但我們認爲人們對下一代‘119改進了治療窗口持樂觀態度。」
The acquisition of ImmPACT Bio for its IMPT-314 introduces complexities that could cloud the narrative. The analyst added that while the potential of '314 is visible, the program appears to lack clinical and commercial synergy, and with limited resources and rising competition, it risks becoming a distraction.
收購ImmPACt Bio以獲得其IMPt-314可能引入可能混淆情節的複雜性。分析師補充說，儘管‘314的潛力可見，該項目似乎缺乏臨床和商業協同性，並且由於資源有限且競爭加劇，存在分散注意力的風險。
An analyst noted that with Lyell's focus on restarting its solid tumor program and expanding into hematology, it's challenging to maintain a positive outlook.
一位分析師指出，由於Lyell專注於重新啓動其固體腫瘤項目並擴展到血液學，難以保持樂觀態度。
It remains uncertain if IMPT-314 can provide significant clinical improvements, and it will likely face tough competition from established players like Gilead Sciences Inc (NASDAQ:GILD), Bristol Myers Squibb & Co (NYSE:BMY), and Novartis AG (NYSE:NVS).
目前尚不清楚IMPt-314能否提供重大臨床改進，並且很可能會面臨來自像吉利德科學公司（納斯達克：GILD）、百時美施貴寶（紐交所：BMY）和諾華製藥（紐交所：NVS）等老牌參與者的激烈競爭。
Price Action: LYEL stock is down 9.16% at $0.86 at last check Wednesday.
股價走勢：LYEL股價在週三最後一次查看時下跌9.16％，爲0.86美元。
- Netflix Restructures Leadership, Bids Farewell to Two Key Executives
- 奈飛重組領導層，向兩位關鍵高管告別
Image created using artificial intelligence via Midjourney.
圖像由Midjourney通過人工智能創建。
譯文內容由第三人軟體翻譯。
